CytomX Therapeutics (CTMX) Expected to Announce Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is projected to post its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect CytomX Therapeutics to post earnings of ($0.08) per share and revenue of $7.3250 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 6:00 PM ET.

CytomX Therapeutics Price Performance

NASDAQ:CTMX opened at $4.81 on Wednesday. The company has a market cap of $814.96 million, a P/E ratio of 12.03 and a beta of 2.44. The firm’s fifty day moving average price is $5.10 and its two-hundred day moving average price is $3.88. CytomX Therapeutics has a one year low of $0.40 and a one year high of $6.35.

Analysts Set New Price Targets

A number of brokerages recently commented on CTMX. Guggenheim initiated coverage on shares of CytomX Therapeutics in a research note on Tuesday, January 20th. They issued a “buy” rating and a $10.00 price target on the stock. Cantor Fitzgerald increased their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Piper Sandler lifted their price target on CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Barclays upped their price objective on CytomX Therapeutics from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Finally, HC Wainwright increased their price objective on CytomX Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Institutional Trading of CytomX Therapeutics

A number of institutional investors have recently modified their holdings of CTMX. Orbimed Advisors LLC acquired a new position in CytomX Therapeutics in the second quarter valued at about $19,208,000. Commodore Capital LP bought a new position in CytomX Therapeutics in the 2nd quarter valued at about $17,462,000. Perceptive Advisors LLC bought a new position in CytomX Therapeutics in the 2nd quarter valued at about $15,876,000. State Street Corp raised its position in shares of CytomX Therapeutics by 697.1% in the 4th quarter. State Street Corp now owns 5,140,931 shares of the biotechnology company’s stock valued at $21,900,000 after buying an additional 4,495,949 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of CytomX Therapeutics during the 2nd quarter worth approximately $6,505,000. 67.77% of the stock is currently owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.